Laurus Labs Limited (BOM:540222)

Market Cap	443.66B
Revenue (ttm)	59.29B
Net Income (ttm)	5.09B
Shares Out	n/a
EPS (ttm)	9.45
PE Ratio	87.19
Forward PE	63.78
Dividend	1.20 (0.14%)
Ex-Dividend Date	May 9, 2025

Volume	99,013
Average Volume	141,422
Open	870.20
Previous Close	874.25
Day's Range	846.00 - 874.45
52-Week Range	390.30 - 922.55
Beta	n/a
RSI	51.14
Earnings Date	Jul 25, 2025

About NV5 Global

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and oral solid formulations for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products. In addition,...

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 2005
• Employees: 6,167
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 540222

Financial Performance

In 2024, Laurus Labs's revenue was 55.54 billion, an increase of 10.18% compared to the previous year's 50.41 billion. Earnings were 3.58 billion, an increase of 123.18%.